E-Mail
NEW YORK, NY (March 1, 2021) By harnessing the immune system against cancer, immunotherapies have revolutionized the way some types of cancer are treated. But most patients across cancer types do not respond, and in most cases, scientists are at a loss as to why.
Researchers at Columbia and MIT have created a new technique that can uncover nearly all of the tricks cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments.
The researchers tested their new technique with cancer cells and matching immune cells from melanoma patients and identified previously unknown resistance mechanisms to immune checkpoint inhibitors, a powerful and widely used class of immunotherapy drugs.
Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer
December 21, 2020 GMT
PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Dec 21, 2020
Servier, a global pharmaceutical Group, and Celsius Therapeutics, a company focused on bringing precision medicine to patients with cancer and autoimmunity, today announced a strategic collaboration focused on the identification and validation of novel colorectal cancer (CRC) drug targets.
“As colorectal cancer remains a leading contributor to cancer deaths worldwide, we see an urgent need to bring forward new therapeutic options for patients. Through this collaboration, we will leverage Celsius’ single-cell genomics platform, machine learning capabilities, and target validation expertise to refine our understanding of the different subtypes of CRC and discover new drug targets with the goal of developing novel pre